Claris Biotherapeutics, Inc.

This early-stage trial is testing an experimental eye drop called CSB-001 in 75 people with limbal stem cell deficiency, a condition where the eye's surface can't heal properly, leading to pain and vision loss. The study will check if the drops are safe and if they help improve s…

This early study tests an experimental eye drop (CSB-001) in 20 people with recent corneal scars (from injury within the last 30 days). Participants use the drops 3-4 times daily for up to 14 days. The main goals are to check safety and see if the drops reduce scar size and impro…

This study watches 500 people with limbal stem cell deficiency (LSCD) to see how the disease changes over time. Researchers will track vision, eye comfort, and physical eye changes using questionnaires and tests. No new treatments are given—the goal is simply to learn more about …